You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1820 Results
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab Deruxtecan - HER2-low Unresectable Locally Advanced or Metastatic Breast Cancer
Mar 2024
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
May 2020
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
May 2020
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
May 2020
Regimen
Intent: Palliative
May 2020
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
May 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Jun 2019
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Nov 2022
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
May 2020
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Adjuvant
May 2020
Regimen
Cancer Type:
Hematologic, 
Myelodysplastic Syndrome (MDS)
Intent: Palliative
Funding:
Exceptional Access Program
    decitabine / cedazuridine - For the treatment of adult patients with myelodysplastic syndromes (MDS), according to clinical criteria
Jan 2023

Pages